Cargando…
Prostate Cancer Tumour Features on Template Prostate-mapping Biopsies: Implications for Focal Therapy [Image: see text] ()
BACKGROUND: Focal therapy is being offered as a viable alternative for men with localised prostate cancer (PCa), but it is unclear which men may be suitable. OBJECTIVE: To determine the proportion of men with localised PCa who are potentially suitable for focal therapy. DESIGN, SETTING, AND PARTICIP...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4062939/ https://www.ncbi.nlm.nih.gov/pubmed/24207133 http://dx.doi.org/10.1016/j.eururo.2013.09.045 |
_version_ | 1782321715196461056 |
---|---|
author | Singh, Paras B. Anele, Chukwuemeka Dalton, Emma Barbouti, Omar Stevens, Daniel Gurung, Pratik Arya, Manit Jameson, Charles Freeman, Alex Emberton, Mark Ahmed, Hashim U. |
author_facet | Singh, Paras B. Anele, Chukwuemeka Dalton, Emma Barbouti, Omar Stevens, Daniel Gurung, Pratik Arya, Manit Jameson, Charles Freeman, Alex Emberton, Mark Ahmed, Hashim U. |
author_sort | Singh, Paras B. |
collection | PubMed |
description | BACKGROUND: Focal therapy is being offered as a viable alternative for men with localised prostate cancer (PCa), but it is unclear which men may be suitable. OBJECTIVE: To determine the proportion of men with localised PCa who are potentially suitable for focal therapy. DESIGN, SETTING, AND PARTICIPANTS: Our institutional transperineal template prostate-mapping (TTPM) biopsy registry of 377 men from 2006 to 2010 identified 291 consecutive men with no prior treatment. INTERVENTION: TTPM biopsies using a 5-mm sampling frame. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Suitability for focal therapy required the cancer to be (1) unifocal, (2) unilateral, (3) bilateral/bifocal with at least one neurovascular bundle avoided, or (4) bilateral/multifocal with one dominant index lesion and secondary lesions with Gleason ≤3 + 3 and cancer core involvement ≤3 mm. Binary logistic regression modelling was used to determine variables predictive for focal therapy suitability. RESULTS AND LIMITATIONS: The median age was 61 yr, and the median prostate-specific antigen was 6.8 ng/ml. The median total was 29 cores, with a median of 8 positive cores. Of 239 of 291 men with cancer, 29% (70 men), 60% (144 men), and 8% (20 men) had low-, intermediate-, and high-risk PCa, respectively. Ninety-two percent (220 men) were suitable for one form of focal therapy: hemiablation (22%, 53 men), unifocal ablation (31%, 73 men), bilateral/bifocal ablation (14%, 33 men), and index lesion ablation (26%, 61 men). Binary logistic regression modelling incorporating transrectal biopsy parameters showed no statistically significant predictive variable. When incorporating TTPM parameters, only T stage was a significant negative predictor for suitability (p = 0.001) (odds ratio: 0.001 [95% confidence interval, 0.000–0.048]). Limitations of the study include potential selection bias caused by tertiary referral practise and lack of long-term results on focal therapy efficacy. CONCLUSIONS: Focal therapy requires an accurate tool to localise individual cancer lesions. When such a test, TTPM biopsy, was applied to men with low- and intermediate-risk PCa, most of the men were suitable for a tissue preservation strategy. |
format | Online Article Text |
id | pubmed-4062939 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Elsevier Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-40629392014-07-01 Prostate Cancer Tumour Features on Template Prostate-mapping Biopsies: Implications for Focal Therapy [Image: see text] () Singh, Paras B. Anele, Chukwuemeka Dalton, Emma Barbouti, Omar Stevens, Daniel Gurung, Pratik Arya, Manit Jameson, Charles Freeman, Alex Emberton, Mark Ahmed, Hashim U. Eur Urol Platinum Priority – Prostate Cancer BACKGROUND: Focal therapy is being offered as a viable alternative for men with localised prostate cancer (PCa), but it is unclear which men may be suitable. OBJECTIVE: To determine the proportion of men with localised PCa who are potentially suitable for focal therapy. DESIGN, SETTING, AND PARTICIPANTS: Our institutional transperineal template prostate-mapping (TTPM) biopsy registry of 377 men from 2006 to 2010 identified 291 consecutive men with no prior treatment. INTERVENTION: TTPM biopsies using a 5-mm sampling frame. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Suitability for focal therapy required the cancer to be (1) unifocal, (2) unilateral, (3) bilateral/bifocal with at least one neurovascular bundle avoided, or (4) bilateral/multifocal with one dominant index lesion and secondary lesions with Gleason ≤3 + 3 and cancer core involvement ≤3 mm. Binary logistic regression modelling was used to determine variables predictive for focal therapy suitability. RESULTS AND LIMITATIONS: The median age was 61 yr, and the median prostate-specific antigen was 6.8 ng/ml. The median total was 29 cores, with a median of 8 positive cores. Of 239 of 291 men with cancer, 29% (70 men), 60% (144 men), and 8% (20 men) had low-, intermediate-, and high-risk PCa, respectively. Ninety-two percent (220 men) were suitable for one form of focal therapy: hemiablation (22%, 53 men), unifocal ablation (31%, 73 men), bilateral/bifocal ablation (14%, 33 men), and index lesion ablation (26%, 61 men). Binary logistic regression modelling incorporating transrectal biopsy parameters showed no statistically significant predictive variable. When incorporating TTPM parameters, only T stage was a significant negative predictor for suitability (p = 0.001) (odds ratio: 0.001 [95% confidence interval, 0.000–0.048]). Limitations of the study include potential selection bias caused by tertiary referral practise and lack of long-term results on focal therapy efficacy. CONCLUSIONS: Focal therapy requires an accurate tool to localise individual cancer lesions. When such a test, TTPM biopsy, was applied to men with low- and intermediate-risk PCa, most of the men were suitable for a tissue preservation strategy. Elsevier Science 2014-07 /pmc/articles/PMC4062939/ /pubmed/24207133 http://dx.doi.org/10.1016/j.eururo.2013.09.045 Text en © 2013 European Association of Urology. Published by Elsevier B.V. http://creativecommons.org/licenses/by/3.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Platinum Priority – Prostate Cancer Singh, Paras B. Anele, Chukwuemeka Dalton, Emma Barbouti, Omar Stevens, Daniel Gurung, Pratik Arya, Manit Jameson, Charles Freeman, Alex Emberton, Mark Ahmed, Hashim U. Prostate Cancer Tumour Features on Template Prostate-mapping Biopsies: Implications for Focal Therapy [Image: see text] () |
title | Prostate Cancer Tumour Features on Template Prostate-mapping Biopsies: Implications for Focal Therapy [Image: see text] () |
title_full | Prostate Cancer Tumour Features on Template Prostate-mapping Biopsies: Implications for Focal Therapy [Image: see text] () |
title_fullStr | Prostate Cancer Tumour Features on Template Prostate-mapping Biopsies: Implications for Focal Therapy [Image: see text] () |
title_full_unstemmed | Prostate Cancer Tumour Features on Template Prostate-mapping Biopsies: Implications for Focal Therapy [Image: see text] () |
title_short | Prostate Cancer Tumour Features on Template Prostate-mapping Biopsies: Implications for Focal Therapy [Image: see text] () |
title_sort | prostate cancer tumour features on template prostate-mapping biopsies: implications for focal therapy [image: see text] () |
topic | Platinum Priority – Prostate Cancer |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4062939/ https://www.ncbi.nlm.nih.gov/pubmed/24207133 http://dx.doi.org/10.1016/j.eururo.2013.09.045 |
work_keys_str_mv | AT singhparasb prostatecancertumourfeaturesontemplateprostatemappingbiopsiesimplicationsforfocaltherapyimageseetext AT anelechukwuemeka prostatecancertumourfeaturesontemplateprostatemappingbiopsiesimplicationsforfocaltherapyimageseetext AT daltonemma prostatecancertumourfeaturesontemplateprostatemappingbiopsiesimplicationsforfocaltherapyimageseetext AT barboutiomar prostatecancertumourfeaturesontemplateprostatemappingbiopsiesimplicationsforfocaltherapyimageseetext AT stevensdaniel prostatecancertumourfeaturesontemplateprostatemappingbiopsiesimplicationsforfocaltherapyimageseetext AT gurungpratik prostatecancertumourfeaturesontemplateprostatemappingbiopsiesimplicationsforfocaltherapyimageseetext AT aryamanit prostatecancertumourfeaturesontemplateprostatemappingbiopsiesimplicationsforfocaltherapyimageseetext AT jamesoncharles prostatecancertumourfeaturesontemplateprostatemappingbiopsiesimplicationsforfocaltherapyimageseetext AT freemanalex prostatecancertumourfeaturesontemplateprostatemappingbiopsiesimplicationsforfocaltherapyimageseetext AT embertonmark prostatecancertumourfeaturesontemplateprostatemappingbiopsiesimplicationsforfocaltherapyimageseetext AT ahmedhashimu prostatecancertumourfeaturesontemplateprostatemappingbiopsiesimplicationsforfocaltherapyimageseetext |